Publications by authors named "Anna Cline-Smith"

Article Synopsis
  • Adenovirus infections are particularly dangerous for immunocompromised individuals, with no FDA-approved treatment currently available, leading to the off-label use of cidofovir which has kidney toxicity.
  • Research has shown that USC-093, an orally administered prodrug, is effective against adenovirus in hamsters, showing less nephrotoxicity compared to traditional treatments.
  • The study details the synthesis of USC-093 and its D-homoserinamide analogue, finding that both have significantly higher potency against adenoviruses compared to cidofovir, particularly highlighting the benefits of USC-093D in terms of efficacy.
View Article and Find Full Text PDF

Milk production during lactation places a high demand for calcium that is fulfilled both from maternal bone resorption and diet. While it is known that mammary gland-derived PTHrP drives bone resorption during lactation, the impact of postpartum estrogen loss on bone has been unclear. We used a case-control study design to test the effect of estrogen loss in lactating mice.

View Article and Find Full Text PDF

Adenovirus infections of immunocompromised patients can cause life-threatening disseminated disease. While there are presently no drugs specifically approved to treat these infections, there are several compounds that showed efficacy against adenovirus in preclinical studies. For any such compound, low toxicity is an essential requirement.

View Article and Find Full Text PDF

Human adenoviruses can cause serious, disseminated infections in immunocompromised patients. For pediatric allogeneic stem cell transplant patients, the case fatality rate can reach 80%. Still, there is no available antiviral drug that is specifically approved by the Food and Drug Administration for the treatment of adenovirus infections.

View Article and Find Full Text PDF

Osteoporosis is the most prevalent metabolic bone disease that affects half the women in the sixth and seventh decade of life. Osteoporosis is characterized by uncoupled bone resorption that leads to low bone mass, compromised microarchitecture and structural deterioration that increases the likelihood of fracture with minimal trauma, known as fragility fractures. Several factors contribute to osteoporosis in men and women.

View Article and Find Full Text PDF

The loss of estrogen (E ) initiates a rapid phase of bone loss leading to osteoporosis in one-half of postmenopausal women, but the mechanism is not fully understood. Here, we show for the first time how loss of E activates low-grade inflammation to promote the acute phase of bone catabolic activity in ovariectomized (OVX) mice. E regulates the abundance of dendritic cells (DCs) that express IL-7 and IL-15 by inducing the Fas ligand (FasL) and apoptosis of the DC.

View Article and Find Full Text PDF

A number of studies in model animal systems and in the clinic have established that RANKL promotes bone resorption. Paradoxically, we found that pulsing ovariectomized mice with low-dose RANKL suppressed bone resorption, decreased the levels of proinflammatory effector T cells and led to increased bone mass. This effect of RANKL is mediated through the induction of FoxP3CD25 regulatory CD8 T cells (Tc) by osteoclasts.

View Article and Find Full Text PDF

Osteoimmunology arose from the recognition that cytokines produced by lymphocytes can affect bone homeostasis. We have previously shown that osteoclasts, cells that resorb bone, act as APCs. Cross-presentation of Ags by osteoclasts leads to expression of CD25 and Foxp3, markers of regulatory T cells in the CD8 T cells.

View Article and Find Full Text PDF